Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Dogwood Therapeutics, Inc.
- 1.2%
- 111.7K
- 1.65
Float 9.46M · Signal8 dilution snapshot · Nov 6, 2026
The cost to borrow DWTX shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 25.8%
- 26
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 111.7K sh |
| Oct 15, 2026 | 62.4K sh |
| Sep 30, 2026 | 38.9K sh |
| Sep 15, 2026 | 74.3K sh |
| Aug 31, 2026 | 89.4K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 15, 2026 | 26 sh |
| Oct 14, 2026 | 1.8K sh |
| Sep 24, 2026 | 38 sh |
| Aug 4, 2026 | 1.0K sh |
| Jun 24, 2026 | 60 sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 16, 2026 | 25.8% |
| Nov 13, 2026 | 47.1% |
| Nov 12, 2026 | 31.8% |
| Nov 11, 2026 | 56.9% |
| Nov 10, 2026 | 77.2% |
130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for DWTX: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 111,693 DWTX shares were sold short (1.18% of a 9.46M-share float, 1.65 days to cover).